Back to top

Image: Bigstock

Bet on These 3 Low-Beta Stocks to Combat Market Volatility

Read MoreHide Full Article

The rapidly spreading new coronavirus variant, Omicron, has induced volatility in the financial market. This is because investors are assessing the possibilities for a renewed lockdown, which could rattle economies worldwide.

Hence, creating a portfolio of low-beta stocks is of utmost importance since the securities will deliver healthy returns and provide a shield against choppy market conditions.

Meaning of Beta

Beta measures the volatility or risk of a particular asset compared to the market. In other words, beta measures the extent of a security’s price movement relative to the market. In this article, we are considering the S&P 500 as the market.

If a stock has beta of 1, then the price of the stock will move with the market. So, the stock is more volatile than the market if its beta is more than 1. In the same way, the stock is not as volatile as the market if its beta is less than 1.

For example, if the market offers a return of 20%, a stock with beta of 3 will return 60%, which is overwhelming. Similarly, when the market slips 20%, the stock will sink 60%, which is devastating.

Screening Criteria:

We have taken beta between 0 and 0.7 as our prime criterion for screening stocks that are less volatile than the market. However, this should not be the only factor to be considered while selecting a winning strategy. We need to take into account other parameters as well that can add value to the portfolio.

Percentage Change in Price in the Last 4 Weeks greater than zero: This ensures that the stocks saw positive price movement over the last month.

Average 20 Day Volume greater than 50,000: A substantial trading volume ensures that the stocks are easily tradable.

Price greater than or equal to $5: They must all be trading at a minimum of $5 or higher.

Zacks Rank equal to 1: Zacks Rank #1 (Strong Buy) stocks indicate that they will significantly outperform the broader U.S. equity market over the next one to three months. You can see the complete list of today’s Zacks #1 Rank stocks here.

Here are three stocks that qualified the screening:

Amphastar Pharmaceuticals, Inc. (AMPH - Free Report) is engaged primarily in developing generic and proprietary inhalation, intranasal and injectable products. The Zacks Consensus Estimate for Amphastar Pharmaceuticals’ earnings per share for 2021 and 2022 has been revised upward over the past 30 days.

Amphastar Pharmaceuticals’ stock has gained 7.2% in the past year, comparing favorably with a decline of 11.8% of the composite stocks belonging to the industry. Amphastar Pharmaceuticals believes that the strength in Primatene Mist, glucagon and epinephrine products have been driving its bottom line.

AMN Healthcare Services Inc. (AMN - Free Report) is a leading provider of staffing services to hospitals and healthcare facilities. The Zacks Consensus Estimate for AMN Healthcare’s earnings per share for 2021 is pegged at $7.32, suggesting a massive year-over-year improvement of 113.4%.

With the most diverse staffing and workforce technology solutions, AMN Healthcare is well placed to generate huge cashflows for years since the United States has been trying to cope with a severe shortage of healthcare professionals in history.

Sensus Healthcare, Inc. (SRTS - Free Report) is a leading manufacturer of superficial radiation therapy devices. The Zacks Consensus Estimate for Sensus Healthcare’s bottom line for 2021 and 2022 has been revised upward over the past 30 days.

Sensus Healthcare’s stock has surged 105.7% over the past year, outpacing the improvement of 5.5% of the composite stocks belonging to the industry.  

You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge.

The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.

Click here to sign up for a free trial to the Research Wizard today.

Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.

Disclosure: Performance information for Zacks’ portfolios and strategies are available at: https://www.zacks.com/performance.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Amphastar Pharmaceuticals, Inc. (AMPH) - free report >>

AMN Healthcare Services Inc (AMN) - free report >>

Sensus Healthcare, Inc. (SRTS) - free report >>